Videos

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

Dr. Schenk on the Evolving Treatment Landscape in Lung Cancer

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Dr. Bunn on Targeting HER3 in NSCLC 

Articles

 Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer. 

ADCs Are Poised to Enter HER2-Mutant NSCLC Armamentarium 

The FDA has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.

FDA Approves Brigatinib for Frontline ALK+ NSCLC

Treatment with entrectinib led to an overall response rate of 77% and a median duration of response of 24.6 months in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated findings of a pooled analysis published in Lancet Oncology.

Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC

Treatment with brigatinib demonstrated a 57% reduction in the risk of disease progression or death compared with crizotinib in patients with advanced ALK-positive non–small cell lung cancer who had not received a prior ALK inhibitor.

University of Colorado Cancer Center

Latest from University of Colorado Cancer Center

New content coming soon, please check back later.